Literature DB >> 1423820

The plasminogen-plasmin system in malignancy.

H C Kwaan1.   

Abstract

The study of the plasminogen-plasmin system has, in the past, contributed much to the understanding of fibrinolysis and thrombolysis. Attention is now focused on the role of the components of this system in many biologic functions. Findings of uPA, its receptor and its inhibitor in many tumor tissues and tumor cell lines, strongly implicate their involvement in tumor invasion, tumor cell proliferation and metastasis. The characteristics of the plasminogen activators, the uPA receptor and the plasminogen activator inhibitors as well as their expression and regulation in tumors and tumor cell lines are reviewed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423820     DOI: 10.1007/bf01307184

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  229 in total

1.  Urokinase-type plasminogen activator antigen and early relapse in breast cancer.

Authors:  F Jänicke; M Schmitt; K Ulm; W Gössner; H Graeff
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

2.  Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition.

Authors:  B Norrman; P Wallén; M Rånby
Journal:  Eur J Biochem       Date:  1985-05-15

Review 3.  Inhibitors of the fibrinolytic enzyme system.

Authors:  N Aoki; P C Harpel
Journal:  Semin Thromb Hemost       Date:  1984-01       Impact factor: 4.180

4.  Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation.

Authors:  M S Meltzer
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

5.  Clotting activation and impairment of fibrinolysis in malignancy.

Authors:  E Rocha; J A Páramo; F J Fernández; B Cuesta; M Hernández; M J Paloma; J Rifón
Journal:  Thromb Res       Date:  1989-06-15       Impact factor: 3.944

6.  Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.

Authors:  G Markus; S M Camiolo; S Kohga; J M Madeja; A Mittelman
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

7.  Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator.

Authors:  Z Werb; C L Mainardi; C A Vater; E D Harris
Journal:  N Engl J Med       Date:  1977-05-05       Impact factor: 91.245

8.  Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.

Authors:  S Kohga; S R Harvey; R M Weaver; G Markus
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

Review 9.  Growth factors in the regulation of plasminogen-plasmin system in tumor cells.

Authors:  J Keski-Oja; K Koli; J Lohi; M Laiho
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

10.  Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.

Authors:  A Wohlwend; D Belin; J D Vassalli
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more
  41 in total

1.  Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Authors:  D Albo; D H Berger; J Vogel; G P Tuszynski
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

2.  Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion.

Authors:  S D Konduri; A Tasiou; N Chandrasekar; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Amorphous protein aggregates stimulate plasminogen activation, leading to release of cytotoxic fragments that are clients for extracellular chaperones.

Authors:  Patrick Constantinescu; Rebecca A Brown; Amy R Wyatt; Marie Ranson; Mark R Wilson
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

4.  In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2.

Authors:  S S Lakka; S D Konduri; S Mohanam; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation.

Authors:  S Selvarajan; L R Lund; T Takeuchi; C S Craik; Z Werb
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

6.  Proteolysis in colorectal cancer.

Authors:  E A Garbett; M W Reed; N J Brown
Journal:  Mol Pathol       Date:  1999-06

7.  High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.

Authors:  Ross Smith; AiQun Xue; Anthony Gill; Christopher Scarlett; Alexander Saxby; Adele Clarkson; Thomas Hugh
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

8.  Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.

Authors:  Martin O Judex; Barbara M Mueller
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

9.  Clinical significance of annexin II expression in human non-small cell lung cancer.

Authors:  Jin-Wei Jia; Kun-Lin Li; Jin-Xing Wu; Shu-Liang Guo
Journal:  Tumour Biol       Date:  2013-03-14

10.  Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis.

Authors:  P Dell'Era; M Mohammadi; M Presta
Journal:  Mol Biol Cell       Date:  1999-01       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.